Evidence map›Paper›PMID 30892739›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2019

In vivo binding of a tau imaging probe, [

Hironobu Endo, Hitoshi Shimada, Naruhiko Sahara, Maiko Ono, Shunsuke Koga, Soichiro Kitamura, Fumitoshi Niwa, Shigeki Hirano, Yasuyuki Kimura, Masanori Ichise and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Brain communications · 2024
    Article
  10. A Machine Learning-Based Approach to Discrimination of Tauopathies Using [Movement disorders : official journal of the Movement Disorder Society · 2022
    Article
  11. Article
  12. Clinical Spectrum of Tauopathies.Frontiers in neurology · 2022
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Evaluation of [Brain communications · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hironobu EndoDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Hitoshi ShimadaDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Naruhiko SaharaDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Maiko OnoDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Shunsuke KogaDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.ORCID 0000-0001-8868-9700
Soichiro KitamuraDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Fumitoshi NiwaDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Shigeki HiranoDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Yasuyuki KimuraDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Masanori IchiseDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Hitoshi ShinotohDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Ming Rong ZhangDepartment of Radiopharmaceuticals Development, Clinical Research Cluster, NIRS, QST, Chiba, Japan.
Satoshi KuwabaraDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Tatsushi TodaDepartment of Neurology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Tetsuya SuharaDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Makoto HiguchiDepartment of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.

Funding

Project 2: Identifying genes and Pathways that impact Tau Toxicity in FTDU54NS100693 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2016 to 2020
$6.2M
NINDS NIH HHS U54 NS100693
6 · The paper itself

Abstract

background[

objectivesTo explore the usefulness of [

methodsWe assessed 13 PSP patients and 13 age-matched healthy control subjects. Individuals negative for amyloid β PET with [

resultsThere were significant differences in binding potential for [

conclusionsOur findings support the in vivo detectability of tau fibrils characteristic of PSP by [

Indexed as

AgedAged, 80 and overAniline CompoundsAutoradiographyBenzothiazolesBrainCarbon RadioisotopesCase-Control StudiesFemaleHumansMaleMiddle AgedPositron-Emission TomographySupranuclear Palsy, Progressivetau ProteinsThiazoles2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAniline CompoundsBenzothiazolesCarbon-11Carbon RadioisotopesPBB3 compoundtau ProteinsThiazolesimagingmovement disordersprogressive supranuclear palsytautau imaging

Identifiers

PMID30892739
PMCPMC6593859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.